IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors
In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on th...
Gespeichert in:
Veröffentlicht in: | Journal of Immunology 2006-01, Vol.176 (2), p.905-913 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 913 |
---|---|
container_issue | 2 |
container_start_page | 905 |
container_title | Journal of Immunology |
container_volume | 176 |
creator | Bui, Jack D Carayannopoulos, Leonidas N Lanier, Lewis L Yokoyama, Wayne M Schreiber, Robert D |
description | In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on these sarcomas, and its expression was selectively down-regulated by either IFN-gamma or IFN-alpha in a manner that was dose- and time-dependent and reversible. Down-regulation occurred at the transcript level and was STAT1-dependent. It also had functional consequences. IFN-gamma-treated MCA sarcomas with high levels of H60 were resistant to killing by IL-2-activated NK cells. Resistance was not solely dependent on enhanced MHC class I expression but rather also required H60 down-regulation. IFN-gamma-treated tumor cells also displayed diminished capacity to down-regulate NKG2D on freshly isolated NK cells. Transplanted tumor cells reisolated from immunocompetent mice displayed reduced H60 expression and increased MHC class I expression compared with tumor cells that were either left unmanipulated or reisolated from mice treated with neutralizing IFN-gamma-specific mAb. This report thus represents the first demonstration that certain cytokines and specifically the IFNs regulate expression of specific NKG2D ligands on murine tumors. This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses. |
doi_str_mv | 10.4049/jimmunol.176.2.905 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67607735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67607735</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-e7c0eafdf72d14f2d1b3c2dd9129b9def6835da0321626466aa0d6d29d63c7233</originalsourceid><addsrcrecordid>eNqFkEtPwkAQxzdGI4h-AQ-mJ2_F2Udn2ZMxII9IMDF43izdLZT0gd02jd_eGjAcvcwc_o_J_Ai5pzAUINTTPs3zpiizIZU4ZEMF0QXp0yiCEBHwkvQBGAs7UfbIjfd7AEBg4pr0KHLFlYz65HkxXYUTd3CFdUUdTMq2CD_ctslMnZZFUCZBvXPB6m3GJsEy3ZrCBnOEoJPWTV5W_pZcJSbz7u60B-Rz-roez8Pl-2wxflmGsZC8Dp2MwZnEJpJZKpJubHjMrFWUqY2yLsERj6wBzigyFIjGgEXLlEUeS8b5gDweew9V-dU4X-s89bHLMlO4svEaJYKUPPrXSKVAMereHxB2NMZV6X3lEn2o0txU35qC_uWr__h2GdRMd3y70MOpvdnkzp4jJ6Dn87t0u2vTymmfmyzr7FS3bXtu-gFIboOl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17464839</pqid></control><display><type>article</type><title>IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors</title><source>MEDLINE</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Bui, Jack D ; Carayannopoulos, Leonidas N ; Lanier, Lewis L ; Yokoyama, Wayne M ; Schreiber, Robert D</creator><creatorcontrib>Bui, Jack D ; Carayannopoulos, Leonidas N ; Lanier, Lewis L ; Yokoyama, Wayne M ; Schreiber, Robert D</creatorcontrib><description>In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on these sarcomas, and its expression was selectively down-regulated by either IFN-gamma or IFN-alpha in a manner that was dose- and time-dependent and reversible. Down-regulation occurred at the transcript level and was STAT1-dependent. It also had functional consequences. IFN-gamma-treated MCA sarcomas with high levels of H60 were resistant to killing by IL-2-activated NK cells. Resistance was not solely dependent on enhanced MHC class I expression but rather also required H60 down-regulation. IFN-gamma-treated tumor cells also displayed diminished capacity to down-regulate NKG2D on freshly isolated NK cells. Transplanted tumor cells reisolated from immunocompetent mice displayed reduced H60 expression and increased MHC class I expression compared with tumor cells that were either left unmanipulated or reisolated from mice treated with neutralizing IFN-gamma-specific mAb. This report thus represents the first demonstration that certain cytokines and specifically the IFNs regulate expression of specific NKG2D ligands on murine tumors. This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.4049/jimmunol.176.2.905</identifier><identifier>PMID: 16393975</identifier><language>eng</language><publisher>United States: Am Assoc Immnol</publisher><subject>Animals ; Base Sequence ; Cell Line, Tumor ; Cell Proliferation ; Cytotoxicity, Immunologic ; DNA, Complementary - genetics ; DNA, Neoplasm - genetics ; Down-Regulation - drug effects ; Histocompatibility Antigens Class I - metabolism ; Humans ; Interferon Type I - pharmacology ; Interferon-gamma - pharmacology ; Killer Cells, Natural - immunology ; Ligands ; Mice ; Mice, Inbred C57BL ; Minor Histocompatibility Antigens - genetics ; Minor Histocompatibility Antigens - metabolism ; Neoplasm Transplantation ; NK Cell Lectin-Like Receptor Subfamily K ; Receptors, Immunologic - metabolism ; Receptors, Natural Killer Cell ; Recombinant Proteins ; Sarcoma, Experimental - drug therapy ; Sarcoma, Experimental - immunology ; Sarcoma, Experimental - pathology ; STAT1 Transcription Factor - metabolism ; Transplantation, Isogeneic</subject><ispartof>Journal of Immunology, 2006-01, Vol.176 (2), p.905-913</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-e7c0eafdf72d14f2d1b3c2dd9129b9def6835da0321626466aa0d6d29d63c7233</citedby><cites>FETCH-LOGICAL-c473t-e7c0eafdf72d14f2d1b3c2dd9129b9def6835da0321626466aa0d6d29d63c7233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16393975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bui, Jack D</creatorcontrib><creatorcontrib>Carayannopoulos, Leonidas N</creatorcontrib><creatorcontrib>Lanier, Lewis L</creatorcontrib><creatorcontrib>Yokoyama, Wayne M</creatorcontrib><creatorcontrib>Schreiber, Robert D</creatorcontrib><title>IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors</title><title>Journal of Immunology</title><addtitle>J Immunol</addtitle><description>In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on these sarcomas, and its expression was selectively down-regulated by either IFN-gamma or IFN-alpha in a manner that was dose- and time-dependent and reversible. Down-regulation occurred at the transcript level and was STAT1-dependent. It also had functional consequences. IFN-gamma-treated MCA sarcomas with high levels of H60 were resistant to killing by IL-2-activated NK cells. Resistance was not solely dependent on enhanced MHC class I expression but rather also required H60 down-regulation. IFN-gamma-treated tumor cells also displayed diminished capacity to down-regulate NKG2D on freshly isolated NK cells. Transplanted tumor cells reisolated from immunocompetent mice displayed reduced H60 expression and increased MHC class I expression compared with tumor cells that were either left unmanipulated or reisolated from mice treated with neutralizing IFN-gamma-specific mAb. This report thus represents the first demonstration that certain cytokines and specifically the IFNs regulate expression of specific NKG2D ligands on murine tumors. This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses.</description><subject>Animals</subject><subject>Base Sequence</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Cytotoxicity, Immunologic</subject><subject>DNA, Complementary - genetics</subject><subject>DNA, Neoplasm - genetics</subject><subject>Down-Regulation - drug effects</subject><subject>Histocompatibility Antigens Class I - metabolism</subject><subject>Humans</subject><subject>Interferon Type I - pharmacology</subject><subject>Interferon-gamma - pharmacology</subject><subject>Killer Cells, Natural - immunology</subject><subject>Ligands</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Minor Histocompatibility Antigens - genetics</subject><subject>Minor Histocompatibility Antigens - metabolism</subject><subject>Neoplasm Transplantation</subject><subject>NK Cell Lectin-Like Receptor Subfamily K</subject><subject>Receptors, Immunologic - metabolism</subject><subject>Receptors, Natural Killer Cell</subject><subject>Recombinant Proteins</subject><subject>Sarcoma, Experimental - drug therapy</subject><subject>Sarcoma, Experimental - immunology</subject><subject>Sarcoma, Experimental - pathology</subject><subject>STAT1 Transcription Factor - metabolism</subject><subject>Transplantation, Isogeneic</subject><issn>0022-1767</issn><issn>1550-6606</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtPwkAQxzdGI4h-AQ-mJ2_F2Udn2ZMxII9IMDF43izdLZT0gd02jd_eGjAcvcwc_o_J_Ai5pzAUINTTPs3zpiizIZU4ZEMF0QXp0yiCEBHwkvQBGAs7UfbIjfd7AEBg4pr0KHLFlYz65HkxXYUTd3CFdUUdTMq2CD_ctslMnZZFUCZBvXPB6m3GJsEy3ZrCBnOEoJPWTV5W_pZcJSbz7u60B-Rz-roez8Pl-2wxflmGsZC8Dp2MwZnEJpJZKpJubHjMrFWUqY2yLsERj6wBzigyFIjGgEXLlEUeS8b5gDweew9V-dU4X-s89bHLMlO4svEaJYKUPPrXSKVAMereHxB2NMZV6X3lEn2o0txU35qC_uWr__h2GdRMd3y70MOpvdnkzp4jJ6Dn87t0u2vTymmfmyzr7FS3bXtu-gFIboOl</recordid><startdate>20060115</startdate><enddate>20060115</enddate><creator>Bui, Jack D</creator><creator>Carayannopoulos, Leonidas N</creator><creator>Lanier, Lewis L</creator><creator>Yokoyama, Wayne M</creator><creator>Schreiber, Robert D</creator><general>Am Assoc Immnol</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20060115</creationdate><title>IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors</title><author>Bui, Jack D ; Carayannopoulos, Leonidas N ; Lanier, Lewis L ; Yokoyama, Wayne M ; Schreiber, Robert D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-e7c0eafdf72d14f2d1b3c2dd9129b9def6835da0321626466aa0d6d29d63c7233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Base Sequence</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Cytotoxicity, Immunologic</topic><topic>DNA, Complementary - genetics</topic><topic>DNA, Neoplasm - genetics</topic><topic>Down-Regulation - drug effects</topic><topic>Histocompatibility Antigens Class I - metabolism</topic><topic>Humans</topic><topic>Interferon Type I - pharmacology</topic><topic>Interferon-gamma - pharmacology</topic><topic>Killer Cells, Natural - immunology</topic><topic>Ligands</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Minor Histocompatibility Antigens - genetics</topic><topic>Minor Histocompatibility Antigens - metabolism</topic><topic>Neoplasm Transplantation</topic><topic>NK Cell Lectin-Like Receptor Subfamily K</topic><topic>Receptors, Immunologic - metabolism</topic><topic>Receptors, Natural Killer Cell</topic><topic>Recombinant Proteins</topic><topic>Sarcoma, Experimental - drug therapy</topic><topic>Sarcoma, Experimental - immunology</topic><topic>Sarcoma, Experimental - pathology</topic><topic>STAT1 Transcription Factor - metabolism</topic><topic>Transplantation, Isogeneic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bui, Jack D</creatorcontrib><creatorcontrib>Carayannopoulos, Leonidas N</creatorcontrib><creatorcontrib>Lanier, Lewis L</creatorcontrib><creatorcontrib>Yokoyama, Wayne M</creatorcontrib><creatorcontrib>Schreiber, Robert D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bui, Jack D</au><au>Carayannopoulos, Leonidas N</au><au>Lanier, Lewis L</au><au>Yokoyama, Wayne M</au><au>Schreiber, Robert D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors</atitle><jtitle>Journal of Immunology</jtitle><addtitle>J Immunol</addtitle><date>2006-01-15</date><risdate>2006</risdate><volume>176</volume><issue>2</issue><spage>905</spage><epage>913</epage><pages>905-913</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><eissn>1365-2567</eissn><abstract>In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on these sarcomas, and its expression was selectively down-regulated by either IFN-gamma or IFN-alpha in a manner that was dose- and time-dependent and reversible. Down-regulation occurred at the transcript level and was STAT1-dependent. It also had functional consequences. IFN-gamma-treated MCA sarcomas with high levels of H60 were resistant to killing by IL-2-activated NK cells. Resistance was not solely dependent on enhanced MHC class I expression but rather also required H60 down-regulation. IFN-gamma-treated tumor cells also displayed diminished capacity to down-regulate NKG2D on freshly isolated NK cells. Transplanted tumor cells reisolated from immunocompetent mice displayed reduced H60 expression and increased MHC class I expression compared with tumor cells that were either left unmanipulated or reisolated from mice treated with neutralizing IFN-gamma-specific mAb. This report thus represents the first demonstration that certain cytokines and specifically the IFNs regulate expression of specific NKG2D ligands on murine tumors. This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses.</abstract><cop>United States</cop><pub>Am Assoc Immnol</pub><pmid>16393975</pmid><doi>10.4049/jimmunol.176.2.905</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1767 |
ispartof | Journal of Immunology, 2006-01, Vol.176 (2), p.905-913 |
issn | 0022-1767 1550-6606 1365-2567 |
language | eng |
recordid | cdi_proquest_miscellaneous_67607735 |
source | MEDLINE; Wiley Free Content; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Animals Base Sequence Cell Line, Tumor Cell Proliferation Cytotoxicity, Immunologic DNA, Complementary - genetics DNA, Neoplasm - genetics Down-Regulation - drug effects Histocompatibility Antigens Class I - metabolism Humans Interferon Type I - pharmacology Interferon-gamma - pharmacology Killer Cells, Natural - immunology Ligands Mice Mice, Inbred C57BL Minor Histocompatibility Antigens - genetics Minor Histocompatibility Antigens - metabolism Neoplasm Transplantation NK Cell Lectin-Like Receptor Subfamily K Receptors, Immunologic - metabolism Receptors, Natural Killer Cell Recombinant Proteins Sarcoma, Experimental - drug therapy Sarcoma, Experimental - immunology Sarcoma, Experimental - pathology STAT1 Transcription Factor - metabolism Transplantation, Isogeneic |
title | IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A54%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IFN-Dependent%20Down-Regulation%20of%20the%20NKG2D%20Ligand%20H60%20on%20Tumors&rft.jtitle=Journal%20of%20Immunology&rft.au=Bui,%20Jack%20D&rft.date=2006-01-15&rft.volume=176&rft.issue=2&rft.spage=905&rft.epage=913&rft.pages=905-913&rft.issn=0022-1767&rft.eissn=1550-6606&rft_id=info:doi/10.4049/jimmunol.176.2.905&rft_dat=%3Cproquest_cross%3E67607735%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17464839&rft_id=info:pmid/16393975&rfr_iscdi=true |